Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:00 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
NCT02668770 · M.D. Anderson Cancer Center · PHASE1 · terminated · last registry update 2026-04-07 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “\<75% participation” | – | Registry record, M.D. Anderson Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TLR9 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-04Results posted on the registry: ProgenaBiome, Hydroxychloroquine (NCT04335084)
- 2026-10-21Results posted on the registry: The University of Texas Health Science Center at San Antonio, Sorafenib (SOR) + Hydroxychloroquine (HCQ) (NCT03037437)
- 2026-10-15Results posted on the registry: Rohit Aggarwal, MD, Nintedanib + Placebo (NCT05799755)
- 2026-10-06Also stopped (terminated): ECOG-ACRIN Cancer Research Group, Dabrafenib mesylate + Hydroxychloroquine (NCT04527549)
- 2026-09-21Phase 3 first posted: Starship Child Health, Te Toka Tumai Auckland, Hydroxychloroquine (HCQ) + Prednisone or Prednisolone (NCT07830108)
- 2026-09-08Also stopped (withdrawn): Apsen Farmaceutica S.A., Hydroxychloroquine Sulfate + Hydroxychloroquine Sulfate + Azythromycin (NCT04361461)
- 2026-08-20Results posted on the registry: VA Office of Research and Development, Hydroxychloroquine + Matching Placebo (NCT03636152)
- 2026-08-05Results posted on the registry: Massachusetts General Hospital, Capecitabine + Hydroxychloroquine (NCT01494155)
- 2026-07-28Phase 3 first posted: Ain Shams University, Nicorandil Oral Tablet + Placebo (NCT07730723)
- 2026-07-21Results posted on the registry: HonorHealth Research Institute, Paclitaxel protein bound + Gemcitabine (NCT04669197)
- 2026-07-20Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), Placebo for VIB4920 + VIB4920 with TNFi (NCT05306353)
- 2026-07-20Also stopped (terminated): National Institute of Allergy and Infectious Diseases (NIAID), Placebo for VIB4920 + VIB4920 with TNFi (NCT05306353)
- 2026-06-18Phase 3 first posted: Chinese SLE Treatment And Research Group, Sirolimus + Placebo (NCT07657793)
- 2026-06-12Also stopped (terminated): Northwestern University, Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab (NCT05576896)
- 2026-05-19Also stopped (withdrawn): Nicholas Carlson, Hydroxychloroquine (NCT05110651)
- 2026-05-14Also stopped (terminated): University of Utah, Hydroxychloroquine + Trametinib (NCT03825289)
- 2026-04-29Also stopped (terminated): Guy's and St Thomas' NHS Foundation Trust, Hydroxychloroquine + Placebo (NCT04316494)
- 2026-04-14Also stopped (terminated): University Hospital, Rouen, Hydroxychloroquine + placebo (NCT02595346)
- 2026-04-13Also stopped (terminated): Cancer Trials Ireland, Trametinib + Hydroxychloroquine (NCT05518110)
- 2026-04-06Also stopped (withdrawn): Assistance Publique - Hôpitaux de Paris, Plaquenil 200Mg Tablet + Placebo oral tablet (NCT04275778)
- 2026-03-27Also stopped (terminated): Incannex Healthcare Ltd, IHL-675A + Cannabidiol (NCT05942911)
- 2026-02-24Results posted on the registry: University of California, San Francisco, Combination Intervention (NCT04357821)
- 2026-02-06Also stopped (terminated): Queen's Medical Center, Hydroxychloroquine (NCT04345692)
- 2026-01-23Results posted on the registry: Emory University, Gemcitabine + Hydroxychloroquine (NCT04524702)
- 2025-12-04Phase 3 first posted: National Taiwan University Hospital, Hydrochloroquine + Placebo (NCT07265297)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision